Influence of DOACS and DOAC-REMOVE® on coagulation assays during thrombophilia testing in DOAC-treated patients

Background/Aim. Direct oral anticoagulants (DOACs) administration significantly interferes with coagulation as-says. The aim of the study was to evaluate effect DOACs and DOAC-Remove? on assays during thrombophilia testing. Methods. carried out from January 2019 end June 2020. It included 30 DOAC-treated patients, 14 females 16 males aged 23 63 (median age 47.6 years), tested for due venous thromboembolism (VTE). Thrombophilia testing performed using tablets (activated charcoal). results before after were compared. Results. Positive lupus anticoagulant (LA) observed in 20% apixaban, 100% dabigatran, 70% rivaroxaban-treated while samples DOAC-Remove?, LA positivity only one apix-aban group. Before activated protein C (APC) resistance (APC-R) measurable 40% dabigatran 80% while, APC-R all cases. Comparing obtained a difference noted relation dilute Russell?s viper venom time (dRVVT) tests, except dRVVT ratio apixaban Clot-based methods detecting APC affected by less rivaroxaban. Conclusion. practically inactivated addition which made it possible perform analyses freely obtain relevant results.